Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematological cells that are retained in corresponding malignant cell types.

Majumder MM, Leppä AM, Hellesøy M, Dowling P, Malyutina A, Kopperud R, Bazou D, Andersson E, Parsons A, Tang J, Kallioniemi O, Mustjoki S, O'Gorman P, Wennerberg K, Porkka K, Gjertsen BT, Heckman CA.

Haematologica. 2019 Aug 22. pii: haematol.2019.217414. doi: 10.3324/haematol.2019.217414. [Epub ahead of print]

2.

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.

Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA.

Haematologica. 2019 Jul 11. pii: haematol.2018.214882. doi: 10.3324/haematol.2018.214882. [Epub ahead of print]

3.

Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.

Karjalainen R, Liu M, Kumar A, He L, Malani D, Parsons A, Kontro M, Kallioniemi O, Porkka K, Heckman CA.

Leukemia. 2019 Oct;33(10):2548-2553. doi: 10.1038/s41375-019-0504-y. Epub 2019 Jun 7. No abstract available.

PMID:
31175323
4.

Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer.

Malyutina A, Majumder MM, Wang W, Pessia A, Heckman CA, Tang J.

PLoS Comput Biol. 2019 May 20;15(5):e1006752. doi: 10.1371/journal.pcbi.1006752. eCollection 2019 May.

5.

Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies.

Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman CA, May P, Hautamäki V, Granberg KJ, Lohi O, Nykter M, Heinäniemi M.

Cancer Res. 2019 May 15;79(10):2466-2479. doi: 10.1158/0008-5472.CAN-18-2970. Epub 2019 Apr 2.

PMID:
30940663
6.

Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.

Karvonen H, Perttilä R, Niininen W, Hautanen V, Barker H, Murumägi A, Heckman CA, Ungureanu D.

Oncogene. 2019 Apr;38(17):3288-3300. doi: 10.1038/s41388-018-0670-9. Epub 2019 Jan 10.

PMID:
30631148
7.

Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder MM, Javarappa KK, Eldfors S, Schwaller J, Porkka K, Heckman CA.

Leukemia. 2019 Jun;33(6):1360-1372. doi: 10.1038/s41375-018-0327-2. Epub 2018 Dec 19.

PMID:
30568173
8.

A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow.

Javarappa KK, Tsallos D, Heckman CA.

SLAS Discov. 2018 Aug;23(7):687-696. doi: 10.1177/2472555218777968. Epub 2018 Jun 4.

PMID:
29865911
9.

Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.

Karvonen H, Chiron D, Niininen W, Ek S, Jerkeman M, Moradi E, Nykter M, Heckman CA, Kallioniemi O, Murumägi A, Ungureanu D.

Blood Adv. 2017 Nov 9;1(24):2257-2268. doi: 10.1182/bloodadvances.2017010215. eCollection 2017 Nov 14.

10.

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.

Alzrigat M, Párraga AA, Majumder MM, Ma A, Jin J, Österborg A, Nahi H, Nilsson K, Heckman CA, Öberg F, Kalushkova A, Jernberg-Wiklund H.

Oncotarget. 2017 Oct 20;8(61):103731-103743. doi: 10.18632/oncotarget.21909. eCollection 2017 Nov 28.

11.

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.

Kuusanmäki H, Dufva O, Parri E, van Adrichem AJ, Rajala H, Majumder MM, Yadav B, Parsons A, Chan WC, Wennerberg K, Mustjoki S, Heckman CA.

Oncotarget. 2017 Oct 31;8(57):97516-97527. doi: 10.18632/oncotarget.22178. eCollection 2017 Nov 14.

12.

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.

Majumder MM, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B, Karjalainen R, Kuusanmäki H, Lievonen J, Parsons A, Suvela M, Jantunen E, Porkka K, Heckman CA.

Oncotarget. 2017 May 5;8(34):56338-56350. doi: 10.18632/oncotarget.17630. eCollection 2017 Aug 22.

13.

The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia.

Kumar A, Kankainen M, Parsons A, Kallioniemi O, Mattila P, Heckman CA.

BMC Genomics. 2017 Aug 17;18(1):629. doi: 10.1186/s12864-017-4039-1.

14.

Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.

Kivioja JL, Lopez Martí JM, Kumar A, Kontro M, Edgren H, Parsons A, Lundán T, Wolf M, Porkka K, Heckman CA.

Leuk Lymphoma. 2018 Mar;59(3):725-732. doi: 10.1080/10428194.2017.1357174. Epub 2017 Aug 4.

PMID:
28776436
15.

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.

Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA.

Blood. 2017 Aug 10;130(6):789-802. doi: 10.1182/blood-2016-02-699363. Epub 2017 Jun 15.

PMID:
28619982
16.

The tumor promoter-activated protein kinase Cs are a system for regulating filopodia.

Heckman CA, Pandey P, Cayer ML, Biswas T, Zhang ZY, Boudreau NS.

Cytoskeleton (Hoboken). 2017 Aug;74(8):297-314. doi: 10.1002/cm.21373. Epub 2017 May 24.

17.

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.

Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K.

Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146.

18.

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.

Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T, Saarela J, Yadav B, Malani D, Fløisand Y, Höglund M, Remes K, Gjertsen BT, Kallioniemi O, Wennerberg K, Heckman CA, Porkka K.

Leukemia. 2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. Epub 2016 Aug 8.

PMID:
27499136
19.

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.

Eldfors S, Kuusanmäki H, Kontro M, Majumder MM, Parsons A, Edgren H, Pemovska T, Kallioniemi O, Wennerberg K, Gökbuget N, Burmeister T, Porkka K, Heckman CA.

Leukemia. 2017 Jan;31(1):51-57. doi: 10.1038/leu.2016.202. Epub 2016 Jul 27.

20.

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.

Pietarinen PO, Pemovska T, Kontro M, Yadav B, Mpindi JP, Andersson EI, Majumder MM, Kuusanmäki H, Koskenvesa P, Kallioniemi O, Wennerberg K, Heckman CA, Mustjoki S, Porkka K.

Blood Cancer J. 2015 May 1;5:e309. doi: 10.1038/bcj.2015.30.

21.

Effect of Cdc42 domains on filopodia sensing, cell orientation, and haptotaxis.

Amarachintha SP, Ryan KJ, Cayer M, Boudreau NS, Johnson NM, Heckman CA.

Cell Signal. 2015 Mar;27(3):683-93. doi: 10.1016/j.cellsig.2014.11.025. Epub 2014 Nov 28.

PMID:
25435426
22.

Statistical detection of quantitative protein biomarkers provides insights into signaling networks deregulated in acute myeloid leukemia.

Elo LL, Karjalainen R, Ohman T, Hintsanen P, Nyman TA, Heckman CA, Aittokallio T.

Proteomics. 2014 Nov;14(21-22):2443-53. doi: 10.1002/pmic.201300460. Epub 2014 Oct 15.

PMID:
25211154
23.

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.

Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserud O, Brümmendorf TH, Edgren H, Gjertsen BT, Itälä-Remes M, Lagström S, Lohi O, Lundán T, Martí JM, Majumder MM, Parsons A, Pemovska T, Rajala H, Vettenranta K, Kallioniemi O, Mustjoki S, Porkka K, Heckman CA.

Leukemia. 2014 Aug;28(8):1738-42. doi: 10.1038/leu.2014.89. Epub 2014 Feb 27. No abstract available.

PMID:
24573384
24.

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K.

Cancer Discov. 2013 Dec;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350. Epub 2013 Sep 20.

25.

Filopodia as sensors.

Heckman CA, Plummer HK 3rd.

Cell Signal. 2013 Nov;25(11):2298-311. doi: 10.1016/j.cellsig.2013.07.006. Epub 2013 Jul 19. Review.

26.

Lamstatin--a novel inhibitor of lymphangiogenesis derived from collagen IV.

Weckmann M, Moir LM, Heckman CA, Black JL, Oliver BG, Burgess JK.

J Cell Mol Med. 2012 Dec;16(12):3062-73. doi: 10.1111/j.1582-4934.2012.01648.x.

27.

Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients.

Jalkanen SE, Lahesmaa-Korpinen AM, Heckman CA, Rantanen V, Porkka K, Hautaniemi S, Mustjoki S.

Exp Hematol. 2012 Sep;40(9):705-714.e3. doi: 10.1016/j.exphem.2012.05.010. Epub 2012 Jun 1.

PMID:
22659387
28.

Somatic STAT3 mutations in large granular lymphocytic leukemia.

Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP Jr, Heckman CA, Maciejewski JP, Mustjoki S.

N Engl J Med. 2012 May 17;366(20):1905-13. doi: 10.1056/NEJMoa1114885.

29.

Unraveling the determinants of protrusion formation.

Varghese M, Gorsevski P, Cayer ML, Boudreau NS, Heckman CA.

Int J Cell Biol. 2012;2012:402916. doi: 10.1155/2012/402916. Epub 2012 Mar 1.

30.

Origin of ruffles: linkage to other protrusions, filopodia and lamellae.

Heckman CA, Varghese M, Cayer ML, Boudreau NS.

Cell Signal. 2012 Jan;24(1):189-98. doi: 10.1016/j.cellsig.2011.08.023. Epub 2011 Sep 10.

PMID:
21930201
31.

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.

McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, Mudie LJ, Hämäläinen E, Stebbings LA, Andersson LC, Flanagan AM, Durbecq V, Ignatiadis M, Kallioniemi O, Heckman CA, Alitalo K, Edgren H, Futreal PA, Stratton MR, Campbell PJ.

Genes Chromosomes Cancer. 2010 Nov;49(11):1062-9. doi: 10.1002/gcc.20815.

32.

Morphological fractal analysis of shape in cancer cells treated with combinations of microtubule-polymerizing and -depolymerizing agents.

Uppal SO, Voronine DV, Wendt E, Heckman CA.

Microsc Microanal. 2010 Aug;16(4):472-7. doi: 10.1017/S1431927610000358. Epub 2010 Jun 22.

PMID:
20569529
33.

Relationship of p21-activated kinase (PAK) and filopodia to persistence and oncogenic transformation.

Heckman CA, Demuth JG, Deters D, Malwade SR, Cayer ML, Monfries C, Mamais A.

J Cell Physiol. 2009 Sep;220(3):576-85. doi: 10.1002/jcp.21788.

PMID:
19384897
34.

Contact inhibition revisited.

Heckman CA.

J Cell Physiol. 2009 Sep;220(3):574-5. doi: 10.1002/jcp.21775.

PMID:
19365807
35.

Functional analysis of FLT4 mutations associated with Nonne-Milroy lymphedema.

Verstraeten VL, Holnthoner W, van Steensel MA, Veraart JC, Bladergroen RS, Heckman CA, Keskitalo S, Frank J, Alitalo K, van Geel M, Steijlen PM.

J Invest Dermatol. 2009 Feb;129(2):509-12. doi: 10.1038/jid.2008.246. Epub 2008 Aug 21. No abstract available.

36.

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.

Cancer Res. 2008 Jun 15;68(12):4754-62. doi: 10.1158/0008-5472.CAN-07-5809.

37.

Pattern analysis of microtubule-polymerizing and -depolymerizing agent combinations as cancer chemotherapies.

Uppal SO, Li Y, Wendt E, Cayer ML, Barnes J, Conway D, Boudreau N, Heckman CA.

Int J Oncol. 2007 Dec;31(6):1281-91.

PMID:
17982653
38.

The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.

Duan H, Heckman CA, Boxer LM.

Oncogene. 2007 Apr 19;26(18):2635-41. Epub 2006 Oct 16.

PMID:
17043638
39.

Actin-based features negatively regulated by protein kinase C-epsilon.

Li Y, Urban JM, Cayer ML, Plummer HK 3rd, Heckman CA.

Am J Physiol Cell Physiol. 2006 Nov;291(5):C1002-13.

40.

Functional interaction of VEGF-C and VEGF-D with neuropilin receptors.

Kärpänen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, Tamagnone L, Alitalo K.

FASEB J. 2006 Jul;20(9):1462-72.

PMID:
16816121
41.

Colchitaxel, a coupled compound made from microtubule inhibitors colchicine and paclitaxel.

Bombuwala K, Kinstle T, Popik V, Uppal SO, Olesen JB, Viña J, Heckman CA.

Beilstein J Org Chem. 2006 Jun 30;2:13.

42.

CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.

Paz-Priel I, Cai DH, Wang D, Kowalski J, Blackford A, Liu H, Heckman CA, Gombart AF, Koeffler HP, Boxer LM, Friedman AD.

Mol Cancer Res. 2005 Oct;3(10):585-96.

43.

Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression.

Heckman CA, Duan H, Garcia PB, Boxer LM.

Oncogene. 2006 Feb 9;25(6):888-98.

PMID:
16186795
44.
45.

Novel p21-activated kinase-dependent protrusions characteristically formed at the edge of transformed cells.

Heckman CA, Urban JM, Cayer M, Li Y, Boudreau N, Barnes J, Plummer HK 3rd, Hall C, Kozma R, Lim L.

Exp Cell Res. 2004 May 1;295(2):432-47.

PMID:
15093742
46.

Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2.

Heckman CA, Cao T, Somsouk L, Duan H, Mehew JW, Zhang CY, Boxer LM.

Cancer Res. 2003 Oct 15;63(20):6666-73.

47.

Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells.

Heckman CA, Wheeler MA, Boxer LM.

Oncogene. 2003 Sep 11;22(39):7891-9.

PMID:
12970736
48.

Allele-specific analysis of transcription factors binding to promoter regions.

Heckman CA, Boxer LM.

Methods. 2002 Jan;26(1):19-26.

PMID:
12054901
49.

NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells.

Heckman CA, Mehew JW, Boxer LM.

Oncogene. 2002 May 30;21(24):3898-908.

50.

Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.

Arcinas M, Heckman CA, Mehew JW, Boxer LM.

Cancer Res. 2001 Jul 1;61(13):5202-6.

Supplemental Content

Loading ...
Support Center